According to Healios’ CEO Hardy TS KAGIMOTO, Helios plans to start clinical trials with iPS-derived RPE in 2017 and hopes for approval in 2020. For international trials, cooperation with Lonza is envisioned.
Nikkei Biotech news release, June 30, 2015
Healios: retinal pigment epithelium (RPE) clinical trials from 2017